AVADEL PHARMACEUTICALS PLC
AVDLUnited States
41 filed reports · 761 financial concepts
Latest figures
Group totals as stated in the company’s own filed reports, each with a link to its report. The change is against the same period a year earlier.
| Figure | Latest fiscal year | Latest quarter |
|---|---|---|
| Revenue | $169MFY2024 · to Dec 31, 2024+505% from $28M10-K | $77.5MQ3 FY2025 · to Sep 30, 2025+54.9% from $50M10-Q |
| Net income | -$48.8MFY2024 · to Dec 31, 2024a year earlier: -$160M10-K | $20KQ3 FY2025 · to Sep 30, 2025a year earlier: -$2.63M10-Q |
| Operating income | -$42.4MFY2024 · to Dec 31, 2024a year earlier: -$138M10-K | $1.94MQ3 FY2025 · to Sep 30, 2025a year earlier: -$327K10-Q |
Filed reports
41 reports · Dec 2014 to Sep 2025Each report counts once it has at least one extracted financial fact.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 30 | 5,436 | Mar 2016 to Sep 2025 |
| Annual · 10-KSEC EDGAR | 10 | 5,244 | Dec 2015 to Dec 2024 |
| Annual · 20-F/ASEC EDGAR | 1 | 622 | Dec 2014 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2025 Q3 | 10-Q | Sep 30, 2025 | Nov 4, 2025 | 326 | Open |
| FY2025 Q2 | 10-Q | Jun 30, 2025 | Aug 7, 2025 | 168 | Open |
| FY2025 Q1 | 10-Q | Mar 31, 2025 | May 7, 2025 | 173 | Open |
| FY2024 | 10-K | Dec 31, 2024 | Mar 3, 2025 | 717 | Open |
| FY2024 Q3 | 10-Q | Sep 30, 2024 | Nov 12, 2024 | 128 | Open |
| FY2024 Q2 | 10-Q | Jun 30, 2024 | Aug 8, 2024 | 113 | Open |
| FY2024 Q1 | 10-Q | Mar 31, 2024 | May 8, 2024 | 109 | Open |
| FY2023 | 10-K | Dec 31, 2023 | Feb 29, 2024 | 368 | Open |
| FY2023 Q3 | 10-Q | Sep 30, 2023 | Nov 8, 2023 | 148 | Open |
| FY2023 Q2 | 10-Q | Jun 30, 2023 | Aug 9, 2023 | 130 | Open |
| FY2023 Q1 | 10-Q | Mar 31, 2023 | May 4, 2023 | 117 | Open |
| FY2022 | 10-K | Dec 31, 2022 | Mar 29, 2023 | 219 | Open |
Financial data
761 concepts · 11,302 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial736 concepts · 10,817 facts · Dec 2007 to Sep 2025
- Common stock par or stated value per share65 · Dec 2013 to Sep 2025
- Cash and cash equivalents at carrying value59 · Dec 2012 to Sep 2025
- Accumulated other comprehensive income loss net of tax58 · Dec 2012 to Sep 2025
- Stockholders equity (US GAAP)57 · Dec 2012 to Sep 2025
- Comprehensive income net of tax56 · Dec 2012 to Sep 2025
- Cost of goods and services sold (US GAAP)56 · Dec 2012 to Sep 2025
- Income tax expense benefit56 · Dec 2012 to Sep 2025
- Increase decrease in accounts payable56 · Dec 2012 to Sep 2025
- Increase decrease in accrued liabilities56 · Dec 2012 to Sep 2025
- Increase decrease in other noncurrent assets and liabilities net56 · Dec 2012 to Sep 2025
- Increase decrease in prepaid deferred expense and other assets56 · Dec 2012 to Sep 2025
- Interest expense debt56 · Dec 2012 to Sep 2025
- Marketable securities current56 · Dec 2012 to Sep 2025
- Net cash provided by used in financing activities56 · Dec 2012 to Sep 2025
- Net cash provided by used in investing activities56 · Dec 2012 to Sep 2025
- Net cash provided by used in operating activities56 · Dec 2012 to Sep 2025
- Net income loss56 · Dec 2012 to Sep 2025
- Operating income loss56 · Dec 2012 to Sep 2025
- Other comprehensive income loss net of tax portion attributable to parent56 · Dec 2012 to Sep 2025
- Payments to acquire marketable securities56 · Dec 2012 to Sep 2025
- Research and development expense56 · Dec 2012 to Sep 2025
- Revenue56 · Dec 2012 to Sep 2025
- Selling general and administrative expense56 · Dec 2012 to Sep 2025
- Share based compensation56 · Dec 2012 to Sep 2025
Product4 concepts · 226 facts · Dec 2013 to Dec 2021
- Revenue135 · Dec 2014 to Mar 2021
- Sales Revenue Goods and Services Net84 · Dec 2013 to Mar 2018
- Costs and expenses6 · Dec 2016 to Dec 2021
- Sales revenue goods gross1 · Dec 2014
Geography7 concepts · 135 facts · Dec 2012 to Dec 2024
- Income loss from continuing operations before income taxes minority interest and income loss from equity method investments69 · Sep 2015 to Dec 2020
- Revenue34 · Dec 2012 to Dec 2020
- Income loss from continuing operations before income taxes extraordinary items noncontrolling interest19 · Dec 2019 to Dec 2024
- Income tax reconciliation tax credits research10 · Dec 2019 to Dec 2023
- Deferred income tax expense benefit1 · Dec 2019
- Increase decrease in deferred income taxes1 · Dec 2019
- Valuation allowance deferred tax asset change in amount1 · Dec 2019
Segment14 concepts · 124 facts · Dec 2022 to Sep 2025
- Cost of goods and services sold (US GAAP)10 · Dec 2022 to Sep 2025
- General and administrative expense (US GAAP)10 · Dec 2022 to Sep 2025
- Gross profit (US GAAP)10 · Dec 2022 to Sep 2025
- Income loss from continuing operations before income taxes extraordinary items noncontrolling interest10 · Dec 2022 to Sep 2025
- Interest expense debt10 · Dec 2022 to Sep 2025
- Investment income net10 · Dec 2022 to Sep 2025
- Operating expenses (US GAAP)10 · Dec 2022 to Sep 2025
- Operating income loss10 · Dec 2022 to Sep 2025
- Research and development expense10 · Dec 2022 to Sep 2025
- Revenue10 · Dec 2022 to Sep 2025
- Segment reporting other item amount10 · Dec 2022 to Sep 2025
- Selling and marketing expense (US GAAP)10 · Dec 2022 to Sep 2025
- Gains losses on extinguishment of debt3 · Dec 2022 to Dec 2024
- Cost Of Product And Service Sold, Net Of Adjustments1 · Sep 2025
Segments
485 factsFigures broken down by business line, region, product or another axis the company reports on.
Statement business segments1 member · 124 facts
- Reportable Segment124 · Dec 2022 to Sep 2025
Product or servicesrt:ProductOrServiceAxis8 members · 120 facts
- Akovaz20 · Dec 2016 to Mar 2021
- Bloxiverz20 · Dec 2016 to Mar 2021
- Vazculep20 · Dec 2016 to Mar 2021
- Other19 · Dec 2016 to Mar 2021
- Product sales15 · Dec 2016 to Dec 2020
- License revenue14 · Dec 2016 to Dec 2020
- Advertising6 · Dec 2016 to Dec 2021
- Noctiva6 · Dec 2016 to Dec 2018
Product or serviceus-gaap:ProductOrServiceAxis6 members · 106 facts
- Bloxiverz28 · Dec 2013 to Jun 2018
- Vazculep27 · Dec 2013 to Jun 2018
- Akovaz19 · Dec 2014 to Jun 2018
- Other17 · Dec 2014 to Jun 2018
- Other [Member]9 · Dec 2013 to Sep 2016
- Noctiva6 · Mar 2017 to Jun 2018
Statement geographicalsrt:StatementGeographicalAxis4 members · 78 facts
- Ireland29 · Dec 2016 to Dec 2023
- United States24 · Dec 2016 to Dec 2024
- France22 · Sep 2017 to Dec 2023
- Europe3 · Dec 2022 to Dec 2024
Statement geographicalus-gaap:StatementGeographicalAxis5 members · 57 facts
- France16 · Dec 2013 to Jun 2018
- Ireland16 · Dec 2013 to Jun 2018
- United States16 · Dec 2013 to Jun 2018
- Other6 · Mar 2016 to Sep 2017
- USA [Member]3 · Dec 2012 to Dec 2014
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
Transcripts with management claims and analyst questions, one per fiscal period.
No earnings-call transcripts for this company.
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Ask about this company in your AI model
Connect FactIQ to Claude, ChatGPT or another AI model (how to install), then paste this prompt.
Use FactIQ to get the revenue, net income and operating income of AVADEL PHARMACEUTICALS PLC (AVDL) from its filed reports, for the last five fiscal years and the latest quarter or half year. Link each figure to its filing, and chart the trend.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Nov 16, 2026) and refreshed every few hours.